Vidamed ceases TUNA physician training and pulls home page after receiving FDA warning letter on July 16.
This article was originally published in The Gray Sheet
Executive Summary
VIDAMED HALTS TUNA BPH SYSTEM PHYSICIAN TRAINING PROGRAM and withdraws the company's home page on the Internet in response to a July 16 FDA warning letter citing the firm for pre-approval promotion of the system. "Upon receipt of the [warning] letter, Vidamed removed its home page from the Internet and canceled all non-clinical investigator training workshops in the United States," Vidamed declared in a July 31 press release.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.